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INTRODUCTION
Hospital admissions and deaths from liver 
disease are rising across the Western 
world.1,2 Most epidemiological studies 
focus on prevalence rates of individual 
diseases in selected hospital populations3 
as much early stage liver disease in 
primary care settings is asymptomatic. 
Alternative strategies include studying 
community cohorts, such as those found to 
have liver-related abnormalities on blood 
testing, or studying diagnostic prevalence 
in computerised primary care records.4–7
Early identification of liver disease 
is important for timely intervention. 
Diagnoses are usually made after 
measurement of liver biochemical tests, 
chiefly alanine transaminase (ALT) 
and aspartate aminotransferase (AST). 
Increasing numbers of liver function tests 
(LFTs) are performed in primary care5,8,9 
for a variety of indications.10,11 Despite high 
rates of testing, a large number of patients 
continue to present to secondary care in the 
later, decompensated, stages of disease, 
suggesting that there are important gaps 
between detecting abnormalities, making 
diagnoses, and implementing treatment.
Abnormal LFTs are not universal in 
chronic liver disease. Long periods in the 
natural history of conditions such as non-
alcoholic fatty liver disease (NAFLD) or 
chronic hepatitis B virus (HBV) infection 
are characterised by transaminase values 
within the reference range, masking 
ongoing liver injury.
In the UK the most common cause 
of liver dysfunction is NAFLD, affecting 
10–30% of the general population, rising 
to 80–90% in obese patients.3,12–16 NAFLD 
is closely linked with other components 
of the metabolic syndrome: obesity, type 
2 diabetes, hypercholesterolaemia, and 
hypertension.17 The prevalence of NAFLD in 
different ethnic groups living in developed 
countries has received little attention. 
The prevalence of hepatic steatosis was 
most common in Hispanic patients in an 
American study,13 and NAFLD may be more 
aggressive in those of Latino origin.18 Little 
is known of prevalence in other populations, 
but given the high rates of metabolic 
syndrome in South Asian populations,19 the 
authors hypothesise that NAFLD is more 
prevalent in these ethnic groups.
A regional database was used to identify 
patients with abnormal LFTs to estimate 
the burden of undiagnosed liver disease 
in primary care. Rates of recorded NAFLD 
were studied in patients from different 
ethnic groups to determine whether South 
Asian ethnicities are at increased risk. 
METHOD
The study was conducted in three east 
London boroughs (Tower Hamlets, 
Newham, and City & Hackney),  where more 
than 50% of the population are from ethnic 
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Abstract
Background
Liver disease is a major cause of morbidity 
and mortality worldwide. Large numbers of 
liver function tests (LFTs) are performed in 
primary care, with abnormal liver biochemistry a 
common finding. Non-alcoholic fatty liver disease 
(NAFLD) is the most common cause of chronic 
liver injury. Metabolic syndrome, common in 
people from South Asia, is an important risk 
factor for NAFLD.
Aim
It is hypothesised that a large gap exists 
between numbers of patients with abnormal 
LFTs and those with recorded liver diagnoses, 
and that NAFLD is more common among 
adults of South Asian ethnic groups.
Design and setting
A cross-sectional study of 690 683 adults in 
coterminous general practices in a region with 
high ethnic diversity. 
Method
Data were extracted on LFTs, liver disease, and 
process of care measures from computerised 
primary care medical records.
Results
LFTs were performed on 218 032 patients, of 
whom 31 627 had elevated serum transaminases. 
The prevalence of abnormal LFTs was highest 
among individuals of Bangladeshi ethnicity. Of 
the patients with abnormal LFTs, 88.4% did 
not have a coded liver diagnosis. NAFLD was 
the most frequently recorded liver disease 
and was most common among Bangladeshi 
patients. In a multivariate analysis, independent 
risk factors for NAFLD included Bangladeshi 
ethnicity, diabetes, raised BMI, hypertension, and 
hypercholesterolaemia.
Conclusion
Abnormal LFTs are common in the population, 
but are underinvestigated and often remain 
undiagnosed. Bangladeshi ethnicity is an 
important independent risk factor for NAFLD.
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minority groups. Data were anonymised and 
extracted from the electronic record for all 
patients aged ≥18 years registered with the 
150 out of 154 GP practices that use the 
EMIS Web clinical system (total 817 700). 
Data were managed according to UK NHS 
information governance requirements.
Demographic variables included age, 
sex, ethnic group, and social deprivation. 
Self-reported ethnic group was collapsed 
into categories: white, Bangladeshi, Indian, 
Pakistani, African, Caribbean, and other 
(including mixed) and not stated (ethnicity 
not determined because of non-response 
or coding error). Social deprivation was 
classified according to the Townsend score.
Liver diagnoses included NAFLD, 
alcoholic liver disease, hepatitis A, B, C, D, 
and E, autoimmune hepatitis, primary biliary 
cirrhosis, primary sclerosing cholangitis, 
haemochromatosis, Wilson’s disease, 
alpha-1 antitrypsin deficiency, portal vein 
thrombosis, Budd Chiari syndrome, 
glycogen storage disorder, cholestasis of 
pregnancy, liver disease in pregnancy, and 
HELLP syndrome. Glandular fever and 
pre-eclampsia were included as causes of 
abnormal transaminases.
Comorbid diabetes, hypertension, and 
cardiovascular disease were recorded. 
Clinical care measures included viral 
serology completion, tobacco and alcohol 
consumption, and latest recorded values 
for body mass index (BMI), serum ALT, AST, 
and lipids. Use of drugs known to commonly 
cause abnormal LFTs was recorded: 
amiodarone, azathioprine, carbamazepine, 
methotrexate, phenytoin, antituberculous 
medications (isoniazid, pyrazinamide, 
rifampicin, ethambutol), and statins.
BMI values were collapsed into four 
categories of underweight (<18.5 kg/m2), 
normal weight (18.5–24.9 kg/m2), overweight 
(25.0–29.9 kg/m2), and obese (≥30.0 kg/
m2). For Bangladeshi, Indian, and Pakistani 
patients, the category cut-offs were set at 
underweight (<18.5 kg/m2), normal weight 
(18.5–22.9 kg/m2), overweight (23.0–27.4 kg/
m2), and obese (≥27.5 kg/m2).20 Alcohol use 
was categorised into within or greater than 
recommended limits (males ≤21 units/week, 
females ≤14 units/week), and ‘not recorded’. 
Statistical analyses were conducted 
using Stata (version 12).
RESULTS
Abnormal liver function in primary care
The study population comprised 690 683 
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How this fits in
Abnormal liver function tests (LFTs) 
are a common finding in primary care, 
and in this study it is shown that many 
patients with such abnormalities have 
no recorded liver diagnoses. Ethnic 
group and components of the metabolic 
syndrome are among key independent 
risk factors for abnormal LFTs, and a 
large number of these patients are likely 
to have undiagnosed non-alcoholic fatty 
liver disease (NAFLD). NAFLD is the most 
common liver diagnosis in the general 
population and being of Bangladeshi, 
but not any other South Asian ethnicity, 
is identified as a novel independent risk 
factor for this condition.
Table 1. Demographic and clinical characteristics of the study population
        Total  
 Bangladeshi Indian Pakistani White African Caribbean population
n 93 315 53 342 31 794 278 944 47 152 23 388 690 683
Mean age, years (SD) 36.5 (14.0) 38.6 (14.8) 37.2 (14.1) 41 (16.3) 40.8 (13.6) 49.7 (17.9) 39.5 (15.4)
Mean Townsend  6.3 (1.7) 4.7 (1.8) 4.8 (1.7) 5.4 (1.9) 5.9 (1.8) 5.6 (1.8) 5.5 (1.9) 
  deprivation score (SD)
Female, n (%) 42 221 (45.2) 23 340 (43.8) 12 353 (38.9) 146 113 (52.4) 24 835 (52.7) 13 227 (56.6) 340 455 (49.3) 
Male, n (%) 51 094 (54.8) 30 002 (56.2) 19 441 (61.1) 132 831 (47.6) 22 317 (47.3) 10 161 (43.4) 350 228 (50.7) 
Diabetes, n (%) 11 554 (12.4) 5028 (9.4) 2991 (9.4) 12 666 (4.5) 3575 (7.6) 3618 (15.5) 47 232 (6.8) 
Hypertension, n (%) 9599 (10.3) 6055 (11.4) 2981 (9.4) 29 910 (10.7) 8078 (17.1) 6540 (28.0) 76 704 (11.1) 
BMI 
  Underweight, n (%) 1482 (1.6) 6225 (11.7) 445 (1.4) 3933 (1.4) 247 (0.5) 149 (0.6) 9458 (1.4)  
  Normal, n (%) 10 352 (11.1) 10 811 (20.3) 3121 (9.8) 74 890 (26.8) 6154 (13.1) 3344 (14.3) 133 287 (19.3)  
  Overweight, n (%) 21 098 (22.6) 10 269 (19.3) 5636 (17.7) 45 331 (16.3) 9404 (19.9) 5112 (21.9) 120 060 (17.4)  
  Obese, n (%) 17 929 (19.2) 25 139 (47.1) 7441 (23.4) 36 211 (13.0) 10 367 (22.0) 6361 (27.2) 106 800 (15.5)
BMI = body mass index. SD = standard deviation. 
adults (Table 1). Ethnicity was recorded 
for 93.1% of the adult population and for 
subsequent analyses, the focus was on the 
six most populous ethnic groups: white, 
Bangladeshi, Pakistani, Indian, African, and 
Caribbean. BMI was recorded for 89.2% 
of all adults, and units of alcohol/week for 
91.0%.
LFTs were performed for 31.6% of 
this population in the previous 2 years 
(n = 218 032 patients; Figure 1). The tested 
population was older than the general 
adult population (49.1 versus 39.4 years). 
Testing varied by ethnicity: 46.5% of adults 
of Caribbean ethnicity had liver testing, 
compared with 40.6% of Bangladeshi, 
37.8% of Pakistani, 36.3% of Indian, 36.0% 
of African, and 28.6% of white adults. Of 
the tested population, 19.1% had diabetes 
(compared with 6.8% of the total adult 
population, P<0.001). 
Among the tested population, 14.5% had 
an ALT or AST elevated above the upper 
limit of the normal range on at least one 
occasion during the 2-year period. The 
key demographic and clinical data for the 
populations with normal and abnormal 
LFTs are shown in Table 2. Within the 
total tested population, the mean ages of 
patients with normal and abnormal LFTs 
were comparable and most patients 
with abnormal LFTs were male. The 
prevalence of abnormal LFTs was highest 
among Bangladeshi (18.4%) and Pakistani 
(17.6%) adults, and lowest among adults 
of Caribbean ethnicity (10.2%), while the 
prevalence rates among patients of Indian 
(14.8%), white (13.5%) and African (11.8%) 
ethnicities were comparable. The mean 
ALT in the group of patients with raised 
transaminases was 67i U/ml (SD = 62.2, 
median 52, interquartile range [IQR] 24) 
and the mean AST was 65 iU/ml (SD 72.5, 
median 46, IQR 24).
The odds of a finding of abnormal LFTs 
in the tested population were calculated 
for a range of potential risk factors in a 
multivariate analysis (Table 3). The odds 
of having abnormal LFTs in the tested 
population were similar in the Bangladeshi 
and white ethnic groups, and significantly 
reduced in patients of Indian, Pakistani, 
African, or Caribbean ethnicity. Key 
independent risk factors for abnormal LFTs 
include male sex, alcohol consumption 
in excess of recommended limits, and 
components of the metabolic syndrome 
(diagnosed diabetes, hypertension, raised 
BMI, and hypercholesterolaemia). There 
was a gradient of risk of abnormal LFTs 
with increasing BMI.
Most liver abnormalities are undiagnosed 
Of the 31 672 patients with abnormal 
transaminases, only 3687 (11.6%) had a 
liver-related diagnosis in the clinical record, 
the most common of which were NAFLD, 
viral infection, and alcoholic liver disease 
(Appendix 1). 
There is no Read Code for drug-induced 
liver injury, but 900 patients were identified 
who were taking medication associated with 
abnormal LFTs (amiodarone, azathioprine, 
carbamazepine, methotrexate, phenytoin, 
and antituberculous medications). In the 
adult population, 87 532 patients (12.7%) 
were prescribed a statin. Of 27 985 patients 
who did not have a diagnosis, 11 111 were 
taking a statin.
Only 494 patients with abnormal LFTs 
had a recorded diagnosis of alcoholic 
liver disease (ALD). Alcohol usage was 
recorded in 28 802 (91.0%) adults with 
abnormal LFTs, of whom 3866 (13.4%) 
were drinking in excess of recommended 
limits. Therefore, in 3372 patients without 
a recorded diagnosis the abnormal LFTs 
were at least associated with alcohol.
Of patients with abnormal LFTs, 6026 
(19.0%) were recorded as drinking within 
recommended limits and had undergone 
testing for viral hepatitis and did not have 
a positive result. This group represents 
a population that may have high rates of 
NAFLD and/or other chronic liver diseases.
Prevalence of recorded diagnosis of liver 
disease
It was reasoned that a large number of 
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Figure 1. Venn diagram showing patients with 
abnormal liver tests and most commonly recorded 
liver diagnoses. (A+B+C+D) = All adults tested 
(n = 218 032); Set A = Tested and normal LFTs 
(n  = 196 360). (B+C) = Tested and abnormal LFTs 
(n = 31 672); Set B = Tested, abnormal LFTs but no 
diagnosis (n = 27 985); Set C = Tested, abnormal 
LFTs and liver diagnosis recorded (n = 3687). 
(C+D+E) = Liver diagnosis recorded; Set D = Tested, 
normal LFTs and liver diagnosis recorded (n = 4384); 
Set E = Not tested, liver diagnosis recorded (n =3965). 
This group of sets is further broken down into the 
proportions of patients with the common liver 
diagnoses. ALD = alcoholic liver disease.  
HBV = hepatitis B virus. HCV = hepatitis C virus.
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patients with liver disease may not have 
abnormal LFTs. Patients with recorded 
liver-related diagnoses in the whole adult 
population were investigated therefore, 
irrespective of biochemical testing. 
A liver-related diagnosis was recorded in 
12 239 (1.7%) of the total adult population. 
The most commonly recorded liver 
diagnosis was NAFLD in 42.9% (n = 5250), 
followed by HBV (23.8%, n = 2910), hepatitis 
C virus (HCV) infection (15.7%, n = 1922), and 
ALD (9.9%, n = 1215). Only 436 (3.6%) had 
more than one liver diagnosis. A diagnosis 
of ALD was most prevalent among people 
of white (0.3%), HBV in people of African 
(1.49%) and HCV in people of Pakistani 
(0.68%) ethnicity (Figure 2).
Not all patients with liver-related 
diagnoses had abnormal LFTs in the 2-year 
period of the study. Liver function tests had 
been performed in 82.5% of patients with 
NAFLD, of whom 55.7% had normal results. 
Risk factors for NAFLD
As NAFLD was the most prevalent liver 
disease, the risk factors for NAFLD in 
the general population were determined. 
Diagnosed NAFLD was significantly more 
prevalent among people of Bangladeshi 
ethnicity (1.8% of the adult population) than 
any other ethnic group, including other 
South Asian groups (Appendices 2 and 
3). As expected, the prevalence of NAFLD 
was significantly lower in the African and 
Caribbean ethnic groups.
The odds of a diagnosis of NAFLD in the 
general adult population were calculated, 
by ethnicity, adjusting for a range of 
previously established risk factors (Table 4). 
The highest risk for NAFLD was in patients 
with raised BMI (with a gradient of risk of 
NAFLD with increasing BMI) and in patients 
with comorbid diabetes or hypertension. 
Other risk factors include hypertension but 
not sex, smoking, age, social deprivation, 
or a diagnosis of cardiovascular disease. 
Bangladeshi, but not Indian or Pakistani, 
ethnicity remained an independent risk 
factor for NAFLD in the adjusted analysis. 
DISCUSSION
Summary
Abnormal liver tests are a common finding 
in primary care,21 yet this study shows that 
most patients with abnormal LFTs who are 
likely to have significant liver disease are 
undiagnosed.
Abnormal LFTs exist in 14.5% of the 
tested population and the marked male 
predilection may be related to alcohol 
consumption22 and HCV infection.23 Ethnicity 
is an independent risk factor for abnormal 
LFTs, with Bangladeshi and white patients 
at higher risk than other groups. Risk factors 
identified in the current study include raised 
BMI and a recorded diagnosis of diabetes, 
both of which are strongly associated with 
NAFLD.
Table 2. Demographic and clinical characteristics of tested patientsa 
with normal and abnormal liver function tests (LFTs)
 Normal LFTs Abnormal LFTs 
 (N  = 186 360) (N  = 31 672) 
Variable n n (%)
Female  108 540 9596 (8.1)
Male  77 820 22 076 (22.1)
Bangladeshi 30 954 6962 (18.4)
Indian  16 507 2876 (14.8)
Pakistani 9917 2111 (17.6)
White 69 028 10 791 (13.5)
African  14 975 2004 (11.8)
Caribbean 9772 1112 (10.2)
Mean age, years (SD) 49.6 (17.4) 47.0 (14.3)
Diabetes  33 673 22 804 (40.4)
Hypertension  52 480 9226 (29.1)
Cardiovascular disease  11 968 6248 (34.2)
a n = 218 032. SD = standard deviation. 
Table 3. Multivariate regression examining the odds of having 
abnormal liver function tests in the previous 2 yearsa
Explanatory variable Odds ratio 95% CI P-value
Ethnicity 
 White (ref) 1 –  
 Bangladeshi 1.09 1.03 to 1.14 0.001 
 Indian 0.84 0.78 to 0.91 <0.001 
 Pakistani 0.92 0.85 to 1.00 0.055 
 African 0.77 0.71 to 0.82 <0.001 
 Caribbean 0.82 0.75 to 0.89 <0.001
Age (continuous) 0.98 0.97 to 0.98 <0.001
Sex 
 Female (ref) 1 –  
 Male 2.94 2.80 to 3.10 <0.001
Diagnosed diabetes 1.58 1.51 to 1.65 <0.001
Diagnosed hypertension 1.16 1.11 to 1.21 <0.001
Diagnosed CVD 0.90 0.84 to 0.95 0.001
BMI category    
 Normal (ref) 1 –  
 Underweight 0.84 0.70 to 0.99 0.042 
 Overweight 1.63 1.53 to 1.74 <0.001 
 Obese 2.44 2.27 to 2.62 <0.001
Alcohol consumption 
 Safe (ref) 1 –  
 Unsafe 1.92 1.80 to 2.05 <0.001
a n = 125 429 out of 218 032 cases with full data sets. Adjusted for Townsend deprivation score, locality and 
clustered by practice (139 clusters). CVD = cardiovascular disease. ref = reference category.
More than half of patients with abnormal 
LFTs had no recorded aetiology or evidence 
of serological investigation, despite the fact 
that detection of even mild derangements 
in LFTs is a significant risk factor for 
liver disease, all-cause and liver-related 
mortality, and despite the higher risk of viral 
liver disease in a multiethnic population.6 
Excess alcohol consumption was common 
among patients with abnormal LFTs 
(13.4%), which is lower than rates reported 
in other series, although it is important 
to remember that a significant proportion 
of patients in the present cohort were 
from religious and social backgrounds in 
which alcohol is rarely consumed or where 
consumption is stigmatised.
A large proportion of patients with 
recorded liver diagnoses did not have 
abnormal LFTs, and this highlights the 
limitation of transaminase testing as 
a screening tool for liver disease.24 Even 
patients with ALT 20–40 iU/ml are at 
increased risk of liver-related mortality and 
this is independent of the liver diagnosis.25 
Furthermore, other key abnormalities in 
liver biochemistry were not recorded — 
gamma-glutamyltransferase or alkaline 
phosphatase — which may be elevated 
in the context of normal transaminases. 
Therefore, it is likely that although this 
study has identified patients with diagnosed 
liver disease and a probable cohort with 
undiagnosed significant liver disease, these 
data still underestimate the true burden of 
liver disease in the population.
Strengths and limitations
This study is the largest community-
based study of the association of ethnicity 
with LFTs and NAFLD to date, and was 
conducted in one of the most ethnically 
diverse regions of the UK. It benefits from 
high levels of data completeness for key 
characteristics: ethnicity, BMI, and alcohol 
consumption. Unlike other cohorts, the 
present data are derived from contiguous 
(unselected) GP practices across the region, 
and therefore include all adult patients. 
This includes practices that specialise in 
the care of homeless persons and injecting 
drug populations. Despite this, it is possible 
that data are lacking from unregistered 
patients who may be among the most 
at-risk sectors of society. 
Although ALT was shown in the BALLETS 
study to be the best liver biochemistry test for 
the exclusion of significant hepatocellular 
disease,26 by focusing on transaminases 
and not alkaline phosphatases, patients 
with biliary disease or hepatobiliary 
tumours may have been overlooked, and 
therefore the true burden of liver disease in 
primary care may well be even higher than 
suggested here.
The EMIS database is principally a clinical 
tool and reflects current practice in primary 
care. There may be bias in data entry, 
therefore, towards mandatory or positive 
data. A priori clinical suspicion usually 
exists, which is not captured in the electronic 
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Table 4. Multivariate regression examining the odds of having 
diagnosed NAFLDa
Explanatory variable Odds ratio 95% CI P-value
Ethnicity 
 White (ref) 1 
 Bangladeshi 1.86 1.56 to 2.23 <0.001 
 Indian 0.94 0.71 to 1.24 0.657 
 Pakistani 1.31 0.99 to 1.74 0.062 
 African 0.58 0.47 to 0.72 <0.001 
 Caribbean 0.45 0.35 to 0.58 <0.001
Age (continuous) 1.01 1.01 to 1.02 <0.001
Sex 
 Female (ref) 1 
 Male 1.02 0.95 to 1.09 0.574
Diagnosed diabetes 2.74 2.51 to 2.99 <0.001
Diagnosed hypertension 1.34 1.15 to 1.57 <0.001
Diagnosed CVD 0.84 0.75 to 0.95 0.007
BMI category 
 Normal (ref) 1 
 Underweight 0.55 0.25 to 1.23 0.148 
 Overweight 4.52 3.72 to 5.51 <0.001 
 Obese 9.59 7.77 to 11.8 <0.001
an = 268 657 out of 690 683 cases with full data sets. Adjusted for Townsend deprivation score, alcohol 
consumption, locality and clustered by practice (139 clusters). CVD = cardiovascular disease. ref = reference 
category.
Figure 2. Prevalence of NAFLD, ALD, HBV and HCV in 
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record, before LFTs are requested. The 
present estimates are comparable with 
published data regarding the distribution 
of liver disease by ethnicity;2,27 HBV is most 
common among Africans, HCV among 
Pakistanis, and ALD among white people. 
However given the ethnic mix in the study 
population, the relatively low rates of viral 
testing in patients with abnormal LFTs 
but without a liver diagnosis suggest a 
diagnostic gap in the estimates of HBV and 
HCV infection rates.
It is not possible to evaluate the accuracy 
of a coded diagnosis of NAFLD, although it is 
likely that most were made after attendance 
at specialist liver clinics. Similarly, among 
the undiagnosed patients with abnormal 
LFTs, it was not possible to determine the 
reasons for the absence of a diagnostic 
code. In some, the abnormality may have 
resolved after a period of watchful waiting, 
or resolution of a concurrent illness.
Comparison with existing literature
This study found that NAFLD was the most 
commonly recorded cause of abnormal 
LFTs in the population in keeping with data 
from others,28 although the prevalence rate 
in the present study is lower than estimates 
from series where the diagnosis was made 
radiologically in the general population or 
histologically in selected series of patients. 
This is partially explained by the high 
proportion of patients in the present cohort 
in whom NAFLD is the probable cause 
of abnormal LFTs but who do not have a 
liver diagnosis. It is also likely that a large 
proportion of patients with NAFLD have 
simply not been diagnosed yet.
The prevalence of recorded NAFLD 
varied considerably by ethnic group. To 
the authors' knowledge, this is the first 
study to identify Bangladeshi ethnicity as 
an independent risk factor for NAFLD, 
albeit in the context of low overall rates 
of liver diagnoses. Among Bangladeshis, 
there are high rates of type 2 diabetes and 
cardiovascular disease that may have a 
genetic basis. Increased prevalence may 
be related to intergenerational influences, 
early years and immigration impacts on 
lifestyle and health beliefs.29,30
Implications for research and practice
Further work is required to understand 
the effect of ethnicity on the natural 
history of NAFLD and why Bangladeshis 
are at increased risk, and, in particular, 
the relative contributions of genetics, diet, 
social deprivation, and cultural health 
behaviours.
The high proportion of patients with 
abnormal LFTs without a diagnosis is a 
challenge to primary care clinicians. Among 
this group many will have a liver disease 
that is amenable to further management, 
which may prevent complications. 
Where a patient has had abnormal LFTs, 
normalisation does not necessarily mean 
that liver injury was transient, as shown by 
the high proportion of patients with NAFLD 
and normal LFTs in the previous 2 years.
The authors recommend that when 
abnormal liver tests are identified, every 
reasonable effort should be made to make 
a diagnosis and to record this. There is a 
need to evaluate the cost-effectiveness of 
increased investigations in primary care 
and onward referral to liver specialists, 
which may be in conflict with current 
financial pressures to reduce laboratory 
tests and traditional outpatient attendance. 
Therefore, the authors support the 
development of evidence-based guidelines 
for the investigation, referral, and 
management of patients with abnormal 
LFTs in the community, to ensure early 
identification of treatable disease.
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Appendix 1. Recorded liver diagnoses in patients with abnormal 
liver function tests
  % of abnormal 
  LFT population 
Diagnosis n (N = 31 672)
NAFLD 1918 6.06
Alcoholic liver disease 494 1.56
Hepatitis B 388 1.23
Hepatitis C 523 1.65
Pregnancy-related 210 0.66
Acute viral infection 178 0.57
Glandular fever 154 0.49
Autoimmune hepatitis 59 0.19
Primary biliary cirrhosis 41 0.13
Primary sclerosing cholangitis 20 0.06
Metabolic 58 0.18
Venous thrombosis 13 0.04
LFT = liver function tests. NAFLD = non-alcoholic fatty liver disease.
Appendix 2. Demographic and clinical characteristics of patients with a recorded diagnosis of NAFLD by 
ethnicity
 Bangladeshi Indian Pakistani White African Caribbean Total
n 1678 325 245 1889 209 143 5250
Prevalence, % 1.8 0.6 0.8 0.7 0.4 0.6 0.8
Mean age, years (SD) 36.5 (14.0) 38.6 (14.8) 37.2 (14.1) 41 (16.3) 40.8 (13.6) 49.7 (17.9) 39.5 (15.4)
Mean Townsend 6.3 (1.7) 4.7 (1.8) 4.8 (1.7) 5.4 (1.9) 5.9 (1.8) 5.6 (1.8) 5.5 (1.9) 
deprivation score (SD)
Diabetes, n (%) 827 (49.3) 125 (38.5) 85 (34.7) 587 (31.1) 76 (36.4) 68 (47.6) 1984 (37.8)
Hypertension, n (%) 558 (33.3) 108 (33.2) 79 (32.2) 815 (43.1) 94 (45.0) 90 (62.9) 2015 (38.4)
BMI
  Underweight, n (%) 0 (0.0) 2 (0.6) 0 (0.0) 5 (0.3) 0 (0.0) 0 (0.0) 9 (0.2) 
  Normal, n (%) 57 (3.4) 9 (2.8) 4 (1.6) 86 (4.6) 9 (4.3) 8 (5.6) 235 (4.5) 
  Overweight, n (%) 492 (29.3) 66 (20.3) 42 (17.1) 403 (21.3) 48 (23.0) 26 (18.2) 1277 (24.3) 
  Obese, n (%) 851 (50.7) 182 (56.0) 159 (64.9) 1005 (53.2) 120 (57.4) 91 (36.6) 2721 (51.8)
BMI = body mass index. SD =  standard deviation. 
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Appendix 3. Prevalence of NAFLD in patients in different age ranges by ethnic group.
